More News! 3 Apr 2019 €21M Series A to Finance Belgian Biotech’s Regenerative Antibodies The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to develop antibody treatments that could regenerate damaged tissue. The round was led by the Belgian… April 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2018 The EMA Approves the First Nanobody from Ablynx …nanobody — a single-domain antibody inspired by those of llamas and camels that combines the specificity of a full antibody with the advantages of having a significantly smaller size. After… September 4, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
In Depth 13 Jul 2022 The biggest European biotech investments in June 2022 …million) in a Series C round to finance the development of antibody drugs that fight cancer by recruiting a type of immune cell called gamma delta T cells. “In a… July 13, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 The 2024 drug approval list: Eight new treatments you should know about …apart from Rytelo and Anktiva, the FDA greenlit Amgen’s T-cell engager Imdelltra for small-cell lung cancer and BeiGene’s monoclonal antibody Tevimbra for esophageal squamous cell carcinoma this year. Later this… June 27, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Brii Bio takes hepatitis B treatment option …collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in phase 2 development. This is… July 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Oct 2018 Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks? …this vaccine could come to market within the decade, as it works by stimulating the body’s antibody response in a conventional manner and so licensing regulations should be less strict…. October 1, 2018 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Nov 2025 Treating endometriosis: what lies ahead? …And with different medicines homed in on different drug targets, the goal is to broaden treatment options. That’s what Hope Medicine wants to do with its monoclonal antibody HMI-115, which has just reaped positive results in a phase… November 5, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2021 EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls …destroying the protective coating of nerve cells called myelin. In the case of Kesimpta, the antibody drug is designed to destroy harmful B cells as does Roche’s Ocrevus, except Kesimpta… April 27, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Gilead Sciences set to acquire MiroBio for $405M …cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective… August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 18 Oct 2019 This Biotech Fights Autoimmune Disease with Rare Immune Cells …specific than existing drugs. The UK biotech MiroBio was founded earlier this month to develop antibody treatments that block immune cells called T-cells from attacking healthy tissue. The Dutch company… October 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer …collaboration to evaluate its lead candidate NY-ESO SPEAR T-cell therapy in combination with MSD’s Keytruda (pembrolizumab). Adaptimmune will sponsor the trial aimed at multiple myeloma, a form of blood cancer… October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2023 InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment …and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults. Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody that acts on the immune system and not… April 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email